Versor Investments LP Has $559,000 Holdings in Charles River Laboratories International, Inc. $CRL

Versor Investments LP cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 52.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,802 shares of the medical research company’s stock after selling 3,086 shares during the quarter. Versor Investments LP’s holdings in Charles River Laboratories International were worth $559,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tema Etfs LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at $26,000. Rothschild Investment LLC grew its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $31,000. Activest Wealth Management grew its stake in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $162.60 on Thursday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of -43.24, a P/E/G ratio of 1.93 and a beta of 1.44. The company’s fifty day moving average is $170.35 and its two-hundred day moving average is $182.83. Charles River Laboratories International, Inc. has a 52-week low of $132.58 and a 52-week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same period last year, the business posted $2.34 EPS. The business’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target on the stock. Citigroup raised their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $205.86.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.